UnitedHealth Group Incorporated (UNH) — closed signal from December 30, 2025
Partial Published before the outcome was known, scored automatically when the window closed on March 30, 2026.
Predicted vs. what happened
What happened
Reached 69% of the predicted growth at its peak, without hitting the target.
The thesis — published December 30, 2025
UnitedHealth can be a defensive, short-term rebound idea if investors move into safer healthcare stocks during a market downturn. Trading shows heavy selling recently but also strong buying volume, which can make a bounce possible. However, company returns on capital have fallen over several years and a new CMS payment plan for GLP-1 drugs adds policy uncertainty, so use small position sizes and wait for a clearer higher low before adding.
Primary drivers
- Healthcare tends to hold up when markets get risky
- New CMS GLP-1 payment rules could change cost views
- Big trading volume near lows supports a short rebound
- Falling ROCE could limit how much the stock can rise
How it played out
UNH: rebound started, target was not reached
Lyra published UNH on 2025-12-30 at $334.74 as a short-term rebound idea with 10% expected growth and a $368.21 target. The thesis pointed to defensive healthcare demand in risky markets, heavy buying volume near lows, CMS GLP-1 payment rules, and falling ROCE as a limit on the move.
Inside the window, UNH rose to $357.87 on 2026-01-23, a 6.9% peak gain. It stayed below the $368.21 target. By 2026-03-30, it ended at $261.79. The bounce partially played out early, but the published target was missed.
What happened during the window
On January 27, 2026, MarketWatch reported that UnitedHealth expected 2026 revenue to decline to greater than $439 billion and guided adjusted earnings per share of at least $17.75. It also reported that CMS proposed a 0.09% Medicare Advantage rate increase for 2027.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.